doi:10.3969/j.issn.1004-583X.2021.12.016

Abstract

CLC Number:

R734.2

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.12.016

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I12/1132

References 31

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. doi: 10.3322/caac.v68.6 URL
[2]	Fearon K, Streasser F, Anker SD, et al. Definition and classification of cancer cachexia: An international consensus[J]. Lancet Oncol, 2011, 12(5):489-495. doi: 10.1016/S1470-2045(10)70218-7 URL
[3]	Chindapasirt J. Sarcopenia in cancer patients[J]. Asian Pac J Cancer Prev, 2015, 16(18):8075-8077. doi: 10.7314/APJCP.2015.16.18.8075 URL
[4]	Yang M, Shen Y, Tan L, et al. Prognostic value of sarcopenia in lung cancer: A systematic review and meta-analysis[J]. Chest, 2019, 156(1):101-111. doi: 10.1016/j.chest.2019.04.115 URL
[5]	Epidemiologic and methodologic problems in determining nutritional status of older persons. Proceedings of a conference. Albuquerque, New Mexico, October 19-21, 1988[J]. Am J Clin Nutr, 1989, 50(5 Suppl):1121-1235. doi: 10.1093/ajcn/50.5.1121 URL
[6]	Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in older people[J]. Age Ageing, 2010, 39(4):412-423. doi: 10.1093/ageing/afq034 pmid: 20392703
[7]	Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: Revised European consensus on definition and diagnosis[J]. Age Ageing, 2019, 48(1):16-31. doi: 10.1093/ageing/afy169 pmid: 30312372
[8]	Kumar V, Benjamin J, Shasthry V, et al. Sarcopenia in cirrhosis: fallout on liver transplantation[J]. J Clin Exp Hepatol, 2020, 10(5):467-476. doi: 10.1016/j.jceh.2019.12.003 URL
[9]	Carey EJ, Lai JC, Sonnenday C, et al. A North American Expert Opinion Statement on sarcopenia in liver transplantation[J]. Hepatology, 2019, 70(5):1816-1829. doi: 10.1002/hep.v70.5 URL
[10]	Park J, Gil JR, Shin Y, et al. Reliable and robust method for abdominal muscle mass quantification using CT/MRI: An explorative study in healthy subjects[J]. PLoS One, 2019, 14(9):e0222042. doi: 10.1371/journal.pone.0222042 URL
[11]	Suzuki Y, Okamoto T, Fujishita T, et al. Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer[J]. Lung cancer, 2016, 101:92-97. doi: S0169-5002(16)30448-2 pmid: 27794415
[12]	Madariaga MLL, Troschel FM, Best D, et al. Low thoracic skeletal muscle area predicts morbidity after pneumonectomy for lung cancer[J]. Ann Thorac Surg, 2020, 109(3):907-913. doi: S0003-4975(19)31830-2 pmid: 31821808
[13]	Takamori S, Tagawa T, Toyokawa G, et al. Prognostic impact of postoperative skeletal muscle decrease in non-small cell lung cancer[J]. Ann Thorac Surg, 2020, 109(3):914-920. doi: 10.1016/j.athoracsur.2019.09.035 URL
[14]	Nishimura JM, Ansari AZ, d' Souza DM, et al. Computed tomography-assessed skeletal muscle mass as a predictor of outcomes in lung cancer surgery[J]. Ann Thorac Surg, 2019, 108(5):1555-1564. doi: S0003-4975(19)30855-0 pmid: 31228408
[15]	Lee J, Moon SW, Choi JS, et al. Impact of sarcopenia on early postoperative complications in early-stage non-small-cell lung cancer[J]. Korean J Thorac Cardiovasc Surg, 2020, 53(3):93-103. doi: 10.5090/kjtcs.2020.53.3.93 URL
[16]	Kim EY, Lee HY, Kim KW, et al. Preoperative computed tomography-determined sarcopenia and postoperative outcome after surgery for non-small cell lung cancer[J]. Scand J Surg, 2018, 107(3):244-251. doi: 10.1177/1457496917748221 pmid: 29284364
[17]	Shinohara S, Otsuki R, Kobayashi K, et al. Impact of sarcopenia on surgical outcomes in non-small cell lung cancer[J]. Ann Surg Oncol, 2020, 27(7):2427-2435. doi: 10.1245/s10434-020-08224-z pmid: 31970570
[18]	Deng HY, Hou L, Zha P, et al. Sarcopenia is an independent unfavorable prognostic factor of non-small cell lung cancer after surgical resection: A comprehensive systematic review and meta-analysis[J]. Eur J Surg Oncol, 2019, 45(5):728-735. doi: 10.1016/j.ejso.2018.09.026 URL
[19]	Kawaguchi Y, Hanaoka J, Ohshio Y, et al. Sarcopenia predicts poor postoperative outcome in elderly patients with lung cancer[J]. Gen Thorac Cardiovasc Surg, 2019, 67(11):949-954. doi: 10.1007/s11748-019-01125-3 URL
[20]	Sun C, Anraku M, Kawahara T, et al. Prognostic significance of low pectoralis muscle mass on preoperative chest computed tomography in localized non-small cell lung cancer after curative-intent surgery[J]. Lung Cancer, 2020, 147:71-76. doi: 10.1016/j.lungcan.2020.07.008 URL
[21]	Sun C, Anraku M, Kawahara T, et al. Respiratory strength and pectoralis muscle mass as measures of sarcopenia: Relation to outcomes in resected non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2020, S0022-5223(20)33059-2.
[22]	Tanaka S, Ozeki N, Mizuno Y, et al. Preoperative paraspinous muscle sarcopenia and physical performance as prognostic indicators in non-small-cell lung cancer[J]. J Cachexia Sarcopenia Muscle, 2021, 12(3):646-656. doi: 10.1002/jcsm.v12.3 URL
[23]	Miura A, Yamamoto H, Sato H, et al. The prognostic impact of sarcopenia on elderly patients undergoing pulmonary resection for non-small cell lung cancer[J]. Surg Today, 2021, 51(7):1203-1211. doi: 10.1007/s00595-020-02221-1 URL
[24]	Stene GB, Helbostad JL, Amundsen T, et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer[J]. Acta Oncol, 2015, 54(3):340-348. doi: 10.3109/0284186X.2014.953259 pmid: 25225010
[25]	Shiroyama T, Nagatomo I, Koyama S, et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study[J]. Sci Rep, 2019, 9(1):2447. doi: 10.1038/s41598-019-39120-6 pmid: 30792455
[26]	Roch B, Coffy A, Jean-Baptiste S, et al. Cachexia-sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors[J]. Lung Cancer, 2020, 143:19-26. doi: 10.1016/j.lungcan.2020.03.003 URL
[27]	Takamori S, Toyokawa G, Okamoto T, et al. Clinical impact and risk factors for skeletal muscle loss after complete resection of early non-small cell lung cancer[J]. Ann Surg Oncol, 2018, 25(5):1229-1236. doi: 10.1245/s10434-017-6328-y URL
[28]	Jang MK, Park C, Hong S, et al. Skeletal muscle mass change during chemotherapy: A systematic review and meta-analysis[J]. Anticancer Res, 2020, 40(5):2409-2418. doi: 10.21873/anticanres.14210 URL
[29]	Kiss N, Beraldo J, Everitt S. Early skeletal muscle loss in non-small cell lung cancer patients receiving chemoradiation and relationship to survival[J]. Support Care Cancer, 2019, 27(7):2657-2664. doi: 10.1007/s00520-018-4563-9 URL
[30]	Kakinuma K, Tsuruoka H, Morikawa K, et al. Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer[J]. Thorac Cancer, 2018, 9(1):99-104. doi: 10.1111/tca.2018.9.issue-1 URL
[31]	Bozzetti F. Chemotherapy-induced sarcopenia[J]. Curr Treat Options Oncol, 2020, 21(1):7. doi: 10.1007/s11864-019-0691-9 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 31

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Li Shufan, Wang Yuxiu, Jiang Zhenghua. The correlation between the prognosis of lung adenocarcinoma with acquired resistance to the first-generation EGFR TKI and the T790M mutation [J]. Clinical Focus, 2022, 37(11): 985-991.
[2]	Huang Ping, Liu Hanyun, Li Yuhong. Risk factors of lung cancer with pulmonary embolism:a meta-analysis [J]. Clinical Focus, 2021, 36(12): 1061-1066.
[3]	Li Guanzhu, Lai Yuan, Zheng Xiaozhuo, Jiang Ran, Wei Ke. Effects of goal-directed fluid therapy on intraoperative balance between oxygen delivery and consumption and postoperative outcomes in thoracic surgery patients: a meta-analysis [J]. Clinical Focus, 2021, 36(8): 677-684.
[4]	Xu Ying, Han Caijuan, Fan Hong, Meng Zerong, Wang Xiaojun, Liu Hua. Relationship between long non-coding RNA overexpression and poor prognostic of small cell lung cancer: a meta-analysis [J]. Clinical Focus, 2021, 36(8): 685-690.
[5]	Wang Ai. Effects of Kangai injection combined with bevacizumab and DP scheme on efficacy and serum tumor markers and prognosis of NSCLC [J]. Clinical Focus, 2021, 36(6): 517-521.
[6]	Yang Ke, Chen Jun. Value of serum NSE, CEA and CA125 levels in diagnosis and efficacy evaluation of patients with small cell lung cancer [J]. Clinical Focus, 2021, 36(3): 225-228.
[7]	Liu Xinyan,Wei Hongyan, Dai Xianli, Liu Ying. Clinical efficacy of chemotherapy combined with location intervened by bronchoscope in central lung cancer [J]. Clinical Focus, 2016, 31(4): 389-391.
[8]	Li Yajie;Chen Kai. Analysis of transbronchial needle aspiration in 224 cases with mediastinal lymphadenectasis [J]. Clinical Focus, 2015, 30(10): 1159-1162.
[9]	. @@ [J]. Clinical Focus, 2015, 30(10): 1197-1200.
[10]	Chi Hongwei;Wang Canghai;Yang Zhiming;Ren Jinjun;Xu Qian;Chen Yanfang. Appilcation of apparent diffusion coefficient value in chemotherapy efficacy evaluation on non-small cell lung carcinoma [J]. Clinical Focus, 2015, 30(8): 883-887.
[11]	Du Junhua;Yin Yifa;Qiao Hongyuan. Effect of maintenance therapy with Huisheng Oral Liquid for patients in mid-advanced non-small cell lung cancer [J]. Clinical Focus, 2015, 30(6): 641-644.
[12]	Hu Shanshan;Zhang Shun;Cai Ting. Immunochemotherapy for advanced non-small cell lung cancer:a meta-analysis [J]. Clinical Focus, 2015, 30(3): 283-289.
[13]	Li Long;Tang Fabing;Yu Qin. Expression of EGFR and RAS/MAPK signal pathway-related proteins and their significance in lung adenocarcinoma [J]. Clinical Focus, 2015, 30(3): 290-292296.
[14]	Chen Yunping;Li Jiancheng;Zhang Jiangling;Hong Chaoxin;Luo Danfeng;Lai Zhangchao. Clinical effect of intensity modulated radiation therapy for treatment of local medium and advanced non-small cell lung cancer [J]. Clinical Focus, 2015, 30(1): 48-5051.
[15]	Huang Jinhong;Yang Jicheng;Zhao Daguo;Xie Yufeng;Ling Chunhua;Sheng Jianhua;Zhao Yungen. Inhibitory and radiosensitizing effects of adenovirus-mediated IL-24 gene on human lung adenocarcinoma [J]. Clinical Focus, 2015, 30(1): 89-94.